Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) Assets Average (2021 - 2025)

Gain Therapeutics has reported Assets Average over the past 5 years, most recently at $10.4 million for Q3 2025.

  • Quarterly results put Assets Average at $10.4 million for Q3 2025, down 38.01% from a year ago — trailing twelve months through Sep 2025 was $10.4 million (down 38.01% YoY), and the annual figure for FY2024 was $15.4 million, down 28.04%.
  • Assets Average for Q3 2025 was $10.4 million at Gain Therapeutics, down from $10.7 million in the prior quarter.
  • Over the last five years, Assets Average for GANX hit a ceiling of $46.7 million in Q2 2021 and a floor of $10.4 million in Q3 2025.
  • Median Assets Average over the past 5 years was $19.8 million (2023), compared with a mean of $24.3 million.
  • Biggest five-year swings in Assets Average: soared 32.85% in 2022 and later tumbled 46.26% in 2023.
  • Gain Therapeutics' Assets Average stood at $40.8 million in 2021, then crashed by 35.71% to $26.2 million in 2022, then tumbled by 37.61% to $16.4 million in 2023, then dropped by 19.01% to $13.2 million in 2024, then dropped by 21.46% to $10.4 million in 2025.
  • The last three reported values for Assets Average were $10.4 million (Q3 2025), $10.7 million (Q2 2025), and $11.9 million (Q1 2025) per Business Quant data.